Jean-Paul Kress is the founder of MorphoSys. Latest round: Growth. Backed by Incyte. Based in Paris, France.
Jean-Paul Kress served as the CEO of MorphoSys from 2019 until its acquisition by Novartis in 2024. During his tenure, he led the development, approval, and commercialization of Monjuvi® (tafasitamab) and advanced the company's pipeline through the acquisition of Constellation Pharmaceuticals in 2021. He also previously served as CEO of Syntimmune until its acquisition by Alexion.
Full founder directory · Investor directory · Company funding database · Fundraising library